The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.

Numerous cytokines have been implicated in the pathogenesis of inflammatory diseases, and their dysregulation is a main feature of rheumatoid arthritis (RA). Cytokines stimulate signal transduction through several intracellular pathways, including Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathways, leading to changes in cell activation, proliferation and survival. Consequently, agents that selectively target elements of the JAK/STAT pathways have received significant attention in recent years as potential new treatments for the disease. Baricitinib, an oral selective inhibitor of JAK1 and JAK2, offers an effective treatment for RA in a wide range of patients. The in vitro selectivity of different JAK inhibitors is an important consideration given that key cytokines, growth factors and hormone receptors involved in the pathogenesis of RA signal through specific JAKs. However, it is complex and far from understood how the in vitro effects of JAK inhibitors extrapolate into in vivo and clinical effects in individual patients. This narrative review focuses on the clinical efficacy and safety of baricitinib, but also provides an overview of its mechanism of action in relation to JAK1/JAK2 signalling and discusses the possible clinical implications in patients with RA.

[1]  Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment , 2019, The Journal of Rheumatology.

[2]  M. Genovese,et al.  THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS , 2019, Poster Presentations.

[3]  M. Weinblatt,et al.  Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis , 2019, Arthritis & rheumatology.

[4]  R. Seetharaman,et al.  MedDRA (Medical Dictionary for Regulatory Activities) , 2018 .

[5]  S. Hider,et al.  Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? , 2018, Drug Safety.

[6]  D. Foell,et al.  JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies , 2018, The Journal of clinical investigation.

[7]  N. Luciano,et al.  One year in review 2018: novelties in the treatment of rheumatoid arthritis. , 2018, Clinical and experimental rheumatology.

[8]  R. Byrne,et al.  Targeted inhibition of Janus kinases abates interfon gamma-induced invasive behaviour of fibroblast-like synoviocytes , 2018, Rheumatology.

[9]  R. Higgs,et al.  P059 Ex vivo comparison of baricitinib, upadacitinib, filgotinib and tofacitinib for cytokine signalling in human leukocyte subpopulations , 2018 .

[10]  E. Lubberts,et al.  The role of IL‐23 receptor signaling in inflammation‐mediated erosive autoimmune arthritis and bone remodeling , 2018, European journal of immunology.

[11]  J. O’Shea,et al.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases , 2017, Nature Reviews Drug Discovery.

[12]  J. O’Shea,et al.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases , 2017, Nature Reviews Drug Discovery.

[13]  L. Tham,et al.  Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis , 2017, CPT: pharmacometrics & systems pharmacology.

[14]  Maria M. Posada,et al.  Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib , 2017, Clinical and translational science.

[15]  N. Udagawa,et al.  A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro , 2017, PloS one.

[16]  M. Genovese,et al.  Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study , 2017, Annals of the rheumatic diseases.

[17]  J. Kremer,et al.  FRI0090 Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis , 2017 .

[18]  M. Dougados,et al.  FRI0096 Durability and maintenance of efficacy following prolonged treatment with baricitinib , 2017 .

[19]  P. Emery,et al.  FRI0124 Temporary interruptions of study drug during the baricitinib phase 3 rheumatoid arthritis program , 2017 .

[20]  J. Kremer,et al.  Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis , 2017, Arthritis & rheumatology.

[21]  H. L. Wright,et al.  Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin‐8, but do not inhibit priming of the respiratory burst or reactive oxygen species production , 2017, Clinical and experimental immunology.

[22]  A. Markham.  Baricitinib: First Global Approval , 2017, Drugs.

[23]  D. M. van der Heijde,et al.  Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment , 2017, Arthritis & rheumatology.

[24]  T. Kakiuchi,et al.  The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases , 2017, Mediators of inflammation.

[25]  D. M. van der Heijde,et al.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis , 2017, The New England journal of medicine.

[26]  Stanley B. Cohen,et al.  Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials , 2017, Annals of the rheumatic diseases.

[27]  M. Dougados,et al.  Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study , 2016, Annals of the rheumatic diseases.

[28]  Yoshiya Tanaka,et al.  Baricitinib for the treatment of rheumatoid arthritis , 2016, Expert review of clinical immunology.

[29]  M. Yuan,et al.  Advances of the interleukin-21 signaling pathway in immunity and angiogenesis. , 2016, Biomedical reports.

[30]  S. Nakayamada,et al.  THU0203 Baricitinib Targets The Type I IFN/STAT-Medicated Activities of Human T Cells and Dendritic Cells , 2016 .

[31]  M. Weinblatt,et al.  THU0209 Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in A Phase 3 Study (RA-BEAM) , 2016 .

[32]  J. Kremer,et al.  Baricitinib in Patients with Refractory Rheumatoid Arthritis. , 2016, The New England journal of medicine.

[33]  Yoshiya Tanaka,et al.  Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study , 2016, The Journal of Rheumatology.

[34]  J. D. Clark,et al.  The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. , 2016, Clinical and experimental rheumatology.

[35]  M. Dougados,et al.  A7.16 Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies , 2016 .

[36]  Zhihong Li,et al.  Multifaceted roles of adiponectin in rheumatoid arthritis. , 2015, International immunopharmacology.

[37]  J. Rodríguez-Frade,et al.  T Cell Migration in Rheumatoid Arthritis , 2015, Front. Immunol..

[38]  D. Wojchowski,et al.  Emerging EPO and EPO receptor regulators and signal transducers. , 2015, Blood.

[39]  W. Williams,et al.  AB0492 Evaluation of Potential Drug-Drug Interactions with Baricitinib , 2015 .

[40]  Cheng Huang,et al.  Interleukin-22 and rheumatoid arthritis: Emerging role in pathogenesis and therapy , 2015, Autoimmunity.

[41]  Yong-sheng Xiao,et al.  Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. , 2015, International journal of oncology.

[42]  Massimo Gadina,et al.  The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.

[43]  P. Scherle,et al.  The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers , 2014, Journal of clinical pharmacology.

[44]  M. Genovese,et al.  Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate , 2014, Annals of the rheumatic diseases.

[45]  Robert J. Moots,et al.  The multifactorial role of neutrophils in rheumatoid arthritis , 2014, Nature Reviews Rheumatology.

[46]  N. Nicola,et al.  The molecular regulation of Janus kinase (JAK) activation. , 2014, The Biochemical journal.

[47]  I. McInnes,et al.  Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. , 2014, Best practice & research. Clinical rheumatology.

[48]  P. Norman.  Selective JAK inhibitors in development for rheumatoid arthritis , 2014, Expert opinion on investigational drugs.

[49]  E. Lee,et al.  Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies , 2014, The Journal of Rheumatology.

[50]  R. Skoda,et al.  Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia , 2014, Haematologica.

[51]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[52]  A. Sinclair.  Erythropoiesis stimulating agents: approaches to modulate activity , 2013, Biologics : targets & therapy.

[53]  S. Choe,et al.  Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans , 2013, PloS one.

[54]  J. O’Shea,et al.  Janus kinase inhibitors in autoimmune diseases , 2013, Annals of the rheumatic diseases.

[55]  J. O’Shea,et al.  Back to the future: oral targeted therapy for RA and other autoimmune diseases , 2013, Nature Reviews Rheumatology.

[56]  Steven M Holland,et al.  JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.

[57]  G. Burmester,et al.  Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease , 2012, Annals of the rheumatic diseases.

[58]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[59]  J. Kremer,et al.  Integrated safety in tocilizumab clinical trials , 2011, Arthritis research & therapy.

[60]  M. Dougados,et al.  Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. , 2011, Clinical and experimental rheumatology.

[61]  A. Gottlieb,et al.  Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. , 2011, Journal of drugs in dermatology : JDD.

[62]  J. Ioannidis,et al.  EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2010, Annals of the rheumatic diseases.

[63]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[64]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[65]  J. Fridman,et al.  Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 , 2010, The Journal of Immunology.

[66]  Stanley B. Cohen,et al.  Kinase inhibitors: a new approach to rheumatoid arthritis treatment , 2010, Current opinion in rheumatology.

[67]  J. Dayer,et al.  Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance? , 2009, Arthritis research & therapy.

[68]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[69]  M. Dougados,et al.  Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy , 2007, Annals of the rheumatic diseases.

[70]  I. McInnes,et al.  Cytokine networks—towards new therapies for rheumatoid arthritis , 2005, Nature Clinical Practice Rheumatology.

[71]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[72]  J. Listing,et al.  The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. , 2013, Rheumatology.

[73]  B. Foxwell,et al.  Signalling , inflammation and arthritis , 2008 .